At the news
? BULLISHIMPACT 6/10 6-K filed Jun 11, 2026 at 06:00 ET
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, showing successful expression/secretion in human cells and specific immune responses with targeted cell-killing. Data will be presented at the EHA 2026 Congress on June 13. This is an early-stage, non-clinical milestone for a pre-revenue biotech with no financial figures or regulatory filing trigger, making it a modest positiveEntwicklung but not a material near-term catalyst.
- EVX-04, an off-the-shelf therapeutic vaccine for AML, achieved complete expression and secretion in human cells, enabling immune recognition and activation
- All 16 ERV antigen fragments included in EVX-04 drive specific immune responses in mice (in vivo) and human cells (in vitro) and induce targeted cell-killing
- Poster presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden on June 13, 2026
- Company states it is preparing regulatory filing for clinical testing
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access